Advanced search
Start date
Betweenand
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

A cell wall protein-based vaccine candidate induce protective immune response against Sporothrix schenckii infection

Full text
Author(s):
Portuondo, Deivys Leandro [1] ; Batista-Duharte, Alexander [2] ; Ferreira, Lucas Souza [1] ; Martinez, Damiana Tellez [1] ; Polesi, Marisa Campos [1] ; Duarte, Roberta Aparecida [1] ; Alves de Paula e Silva, Ana Carolina [1] ; Marcos, Caroline Maria [1] ; Fusco de Almeida, Ana Marisa [1] ; Carlos, Iracilda Zeppone [1, 3]
Total Authors: 10
Affiliation:
[1] Univ Estadual Paulista UNESP, Dept Clin Anal, Araraquaras Sch Pharmaceut Sci, Julio Mesquita Filho, Rua Expedicionarios Brasil 1621, BR-14801902 Araraquara, SP - Brazil
[2] Med Sci Univ, Toxicol & Biomed Ctr TOXIMED, Immunotoxicol Lab, Autopista Nacl Km 1 1-2CP 90400, AP 4033, Santiago De Cuba - Cuba
[3] Univ Estadual Paulista UNESP, Dept Biosci & Biotechnol Appl Pharm, Araraquaras Sch Pharmaceut Sci, Julio Mesquita Filho, Rua Expedicionarios Brasil 1621, BR-14801902 Araraquara, SP - Brazil
Total Affiliations: 3
Document type: Journal article
Source: Immunobiology; v. 221, n. 2, p. 300-309, FEB 2016.
Web of Science Citations: 27
Abstract

Sporotrichosis is a subcutaneous mycosis caused by several closely related thermo-dimorphic fungi of the Sporothrix schenckii species complex, affecting humans and other mammals. In the last few years, new strategies have been proposed for controlling sporotrichosis owning to concerns about its growing incidence in humans, cats, and dogs in Brazil, as well as the toxicity and limited efficacy of conventional antifungal drugs. In this study, we assessed the immunogenicity and protective properties of two aluminum hydroxide (AH)-adsorbed S. schenckii cell wall protein (ssCWP)-based vaccine formulations in a mouse model of systemic S. schenckii infection. Fractioning by SDS-PAGE revealed nine protein bands, two of which were functionally characterized: a 44 kDa peptide hydrolase and a 47 kDa enolase, which was predicted to be an adhesin. Sera from immunized mice recognized the 47 kDa enolase and another unidentified 71 kDa protein, whereas serum from S. schenckii-infected mice recognized both these proteins plus another unidentified 9.4 kDa protein. Furthermore, opsonization with the anti-ssCWP sera led to markedly increased phagocytosis and was able to strongly inhibit the fungus' adhesion to fibroblasts. Immunization with the higher-dose AH-adjuvanted formulation led to increased ex vivo release of IL-12, IFN-gamma, IL-4, and IL-17, whereas only IL-12 and IFN-gamma were induced by the higher-dose non-adjuvanted formulation. Lastly, passive transference of the higher-dose AH-adjuvanted formulation's anti-ssCWP serum was able to afford in vivo protection,in a subsequent challenge with S. schenckii, becoming a viable vaccine candidate for further testing. (C) 2015 Elsevier GmbH. All rights reserved. (AU)

FAPESP's process: 12/24187-0 - Th17 response and apoptosis in the evolution of Sporothrix schenckii-induced infection
Grantee:Iracilda Zeppone Carlos
Support Opportunities: Regular Research Grants